Non Small Cell Lung Cancer
Conditions
Keywords
Met fragments expression
Brief summary
Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.
Detailed description
* Patient information and collection of signed inform consent * Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment. * Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin) * Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte) * Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin) * Selection of blocks of interest and preparation of tumor samples * Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2 * Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test) * Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille
Interventions
OTHERMet analysis on tissue and blood
10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
Sponsors
Centre Oscar Lambret
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with non small cell lung cancer (NSCLC) * Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage) * Treatment naive patient for metastatic NSCLC * Patients with or without neoadjuvant therapy for localized NSCLC * Male or female patients aged ≥ 18 years * Patient registered with the social security system * Having signed a written Informed Consent
Exclusion criteria
* Malignant tumors which are not carcinoma * Small-cell malignant tumors * Secondary bronchial lesions * Revision surgery * Pregnant or breastfeeding women * Patient under guardianship or tutorship * Previous cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression and localization of Met C-terminal active fragments in NSCLC | baseline | Western Blot and immunohistochemistry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the activation of Met receptor | baseline | Activation of Met receptor by immunochemical analysis (Western Blot) |
| Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival | baseline | Relationships between Met receptor expression and sex, TNM, EGFR status, histology, smoking status, survival |
| Expression in plasma of N-terminal Met fragments | baseline | ELISA test |
Countries
France
Contacts
STUDY_DIRECTOREric DANSIN, MD
Centre Oscar Lambret
STUDY_DIRECTORDavid TULASNE, PhD
Institute of Biology of Lille
Outcome results
None listed